The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.

The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.

Bibliographic Details
Main Authors: Kottaridis, P, Gale, R, Frew, M, Harrison, G, Langabeer, SE, Belton, A, Walker, H, Wheatley, K, Bowen, D, Burnett, A, Goldstone, A, Linch, D
Format: Journal article
Published: 2000

Similar Items